Emcure Pharma Share Price in Focus on Signing Distribution Deal with Sanofi India

Emcure Pharmaceuticals and Sanofi India, on July 16, 2025, announced an exclusive distribution and promotion agreement. The deal covers Sanofi’s oral anti-diabetic (OAD) products for the Indian market.

The agreement includes products such as Amaryl and Cetapin, 2 widely prescribed OAD brands. Emcure will handle the distribution and promotion of these drugs across India.

Sanofi to Continue Manufacturing

Sanofi India will retain ownership and continue manufacturing the OAD products. Manufacturing will take place at Sanofi’s existing facilities in India and overseas. There will be no transition of employees between the 2 companies. The arrangement is focused purely on product distribution and promotion.

Emcure will use its existing distribution network and connect with healthcare professionals to increase the availability of these drugs. The plan is to expand access across the country.

Product Reach

Sanofi’s OAD brands are already present in the Indian market. This agreement aims to extend their reach through Emcure’s wider on-ground presence.

The products will continue to be manufactured as per current standards. There will be no changes in formulation, packaging, or ownership of the medicines.

Read more: Emcure Pharma to Buy Remaining 20.42% Stake in Zuventus Healthcare!

Emcure Pharmaceuticals Share Price Performance 

As of 9:24 AM on July 17, 2025, Emcure Pharmaceuticals share price was trading at ₹1,386.90, a 1.79% increase. 

Conclusion

Emcure will take charge of distributing and promoting Sanofi’s oral diabetes drugs in India, while Sanofi retains manufacturing and ownership. The partnership begins immediately, with no change to product composition or company personnel.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.